A Single-center, Open-Label, Drug Interaction Study to Determine the Effects of Apatinib on the Metabolism of CYP3A4/5 and CYP2C9 Probe Drugs in Patients With Solid Tumors

Trial Profile

A Single-center, Open-Label, Drug Interaction Study to Determine the Effects of Apatinib on the Metabolism of CYP3A4/5 and CYP2C9 Probe Drugs in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Rivoceranib (Primary) ; Nifedipine; Warfarin
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 06 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 16 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top